The CF33-hNIS (VAXINIA) technology of Imugene Ltd (ASX:IMU, OTC:IUGNF) (Imugene Ltd (ASX:IMU, OTC:IUGNF), Imugene Ltd (ASX:IMU, OTC:IUGNF)) will feature at the 2024 Cholangiocarcinoma Foundation Annual Conference, having been selected for a short oral presentation during the Basic Science Research Seminar Abstract Session on Thursday, April 18.
The abstract, titled ‘CF33-hNIS, a novel oncolytic virus for the treatment of cholangiocarcinoma and biliary tract malignancies,’ concludes that CF33-hNIS monotherapy may be an effective and safe treatment option for gastrointestinal (GI) malignancies, including cholangiocarcinoma or cancer of the bile ducts, a rare disease with an unmet medical need.
Cholangiocarcinoma conference
The Cholangiocarcinoma conference is dedicated to developing the understanding and treatment of bile duct cancer.
The 11th annual conference in 2024 will be held at the Salt Palace Convention Center in Salt Lake City, Utah, bringing together a wide variety of stakeholders, including medical professionals, researchers, patients and caregivers.
Cholangiocarcinoma is a rare and aggressive form of cancer that occurs in the bile ducts, which are the small tubes that carry the digestive fluid bile from the liver to the small intestine.
Early detection is challenging, and because of its aggressiveness, the prognosis for cholangiocarcinoma can be poor, making research and advancements in treatment essential.
If the cancer is caught before it spreads beyond the bile ducts, five-year survival rates are between 18% to 23%. That number drops to 2% to 3% once the cancer has metastasised.